Cantor Fitzgerald reiterates Novavax stock rating on partnership success

Cantor Fitzgerald reiterated an Overweight rating on Novavax (NVAX) with a $18.00 price target, citing a $125M milestone payment. NVAX shares trade at $9.40, down 17.76% in a week. The company reported narrower-than-expected Q2 2026 losses and beat revenue forecasts, raising its full-year sales outlook. NVAX focuses on licensing its Nuvaxovid vaccine and Matrix-M adjuvant technology.

Original reporting
Published Oct 27, 2026, 12:46 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 1:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$NVAX
Bullish
medium confidence
Mentioned
$NVAX
Relevance
4/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$NVAXBullishLow
01

Why it matters

The rating and cash milestone could modestly lift NVAX, but broader market focus is elsewhere.

02

Market read

Small upside catalyst for NVAX; limited broader market effect.

03

What to watch

Potential competition from Moderna/Merck melanoma trial news could distract investors.

Relevance 4/10Novelty 2/10Timing: post‑market today

Background

Analyst reiterates rating after milestone payment and Q2 earnings beat.

Company-level read

Ticker impact

$NVAXBullishMedium confidence
Context

Cantor Fitzgerald reiterated an Overweight rating on Novavax and highlighted a $125 million milestone payment and Q2 earnings beat.

Expected impact

likely upward pressure as investors price in the higher target and cash milestone.

Evidence & confidence

The rating change and cash receipt are new analyst-driven catalysts, but the earnings beat was already public.

Market effects

Positive signal for biotech licensing models.

Limited to US biotech investors.

Minor, confined to NVAX shareholders.

Counterpoint

The milestone may be a one‑off and earnings beat modest; price may stay flat.

Key entities

  • Novavax Inc.

    Biotech firm developing vaccines.

  • Cantor Fitzgerald

    Equity research firm issuing the rating.

Related articles

$NVAXHighAI 8/10

Novavax (NVAX) stock trades up, here is why

Novavax (NVAX) shares rose 8.8% after reporting Q3 2026 revenue of $68M and raising its full-year revenue outlook to $400M midpoint. The company also received a $125M milestone payment. NVAX reported a net loss of $31M, narrower than the prior year's $202M loss. The stock is up 49.4% YTD but remains 16.9% below its 52-week high.

$NVAXMed

Novavax Q3 Earnings Call Highlights

Novavax reported Q3 revenue of $68M, down from $70M YoY, with a net loss of $31M, improved from a $202M loss last year. The company reduced expenses by 41% YoY and expects its cash runway to extend into 2029. Novavax plans to start clinical testing for its C. diff vaccine candidate in 2027 and is exploring oncology applications for its Matrix-M adjuvant. The company aims to reduce expenses to $150M-$200M by 2028.

$NVAXMed

Novavax (NVAX) Q3 2026 Earnings Call Transcript

Novavax (NVAX) reported Q3 2026 earnings, highlighting a $125 million milestone from Sanofi's phase III trial of a combination flu-COVID vaccine. The company expects additional milestones and revenue from partnerships. Novavax also plans to advance its C. diff vaccine candidate and expand into oncology. The company raised its full-year revenue outlook and improved expense guidance.